In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

A local stem cell therapy company added several new investors as part of its Series A expansion. Learn more here.

The redesigned website features enhanced navigation, expanded technical content, updated service descriptions, and new resources to help biotechnology companies evaluate development and manufacturing ...

The suite of tools is designed to allow AI to carry out R&D work more quickly, reliably, and in a continuous innovation loop.

This year, we aim to focus on demonstrating our expanded production capabilities. With the completion of the acquisition of ...

The financing, led by The Column Group, with participation from Euclidean Capital, Samsara BioCapital, and Sanofi Ventures, will fund the development of Nura Bio’s clinical pipeline, including the ...

By Deena Beasley SAN DIEGO, June 23 (Reuters) - U.S. biotechnology industry trade group BIO worked with the Food and Drug ...

Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.

Boundless Bio (BOLD) merges with Serapha Bio in an all-stock deal; $230M financing funds SERP-01 trials into 2029 and a $44–48M dividend.

Bio-Techne rose 4% on a report that activist investor Ananym Capital Management has accumulated a stake in the maker of ...